DOCSLIB.ORG

WASM-2015-Korea-Abstracts.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WASM-2015-Korea-Abstracts.Pdf Sleep Medicine 16 (2015) S1 Contents lists available at ScienceDirect Sleep Medicine journal homepage: www.elsevier.com/locate/sleep WASM 2015 editorial Dear Colleagues and Friends, character and reach of WASM in collaboration with the knowledge On behalf of the World Association of Sleep Medicine (WASM) of the local Korean Society of Sleep Medicine bring the best of sleep and the Korean Society of Sleep Medicine (KSSM), we are delight- medicine to Korea. Your involvement in this congress will be greatly ed to welcome you to our joint congress: the 6th World Congress valued. You may learn and also share knowledge and skills that will on Sleep Medicine, from March 21 to 25, 2015 at Seoul Korea. The advance sleep health around the world. We hope that you’ll enjoy congress provides an international discussion forum of sleep pro- the science, learning, collegiality, and social events at our world sleep fessionals from the entire world. It focuses particularly on the conference in this historic city with great food, culture, art, and music. interdisciplinary character of our field. Sleep clinicians, technolo- Welcome to Seoul! gists, trainees, educators and scientists from around the world will Best regards, meet here to advance knowledge on sleep science; sleep in public health; sleep health; and the sleep–wake disorders, diagnosis, and Allan O’Bryan * treatments. We seek to maximize learning both from formal pre- World Association of Sleep Medicine, 3270 19th St NW, Suite 110, sentations by leading experts in their fields and from informal Rochester, MN 55901, USA discussion groups emphasizing opportunities for your participa- *Tel.: +1 507 206 1235; fax: +1 877 659 0760. tion. The social events and the Asian culture of Korea support E-mail address: [email protected] productive professional and personal interactions. The global Available online 26 February 2015 http://dx.doi.org/10.1016/j.sleep.2015.02.525 1389-9457/Published by Elsevier B.V. Sleep Medicine 16 (2015) S2–S199 Contents lists available at ScienceDirect Sleep Medicine journal homepage: www.elsevier.com/locate/sleep Abstracts for the 6th World Congress on Sleep Medicine, 23 March to 25 March 2015 Altered sleep architecture in autosomal dominant Acknowledgements: Department of Neurology, NIMHANS, De- spinocerebellar ataxias: A polysomnographic based study partment of Neurophysiology, NIMHANS. S. Donilparthi 1,R.Yadav1, A. Sasidharan 2,P.Pal1, S. Jain 3, B. Kutty 2 http://dx.doi.org/10.1016/j.sleep.2015.02.003 1 Department of Neurology, NIMHANS, Bangalore, India 2 Department of Neurophysiology, NIMHANS, Bangalore, India 3 Molecular Genetics Laboratory, NIMHANS, Bangalore, India Diagnosing REM sleep behaviour disorder in patients with Parkinson’s disease: The role of screening questionnaires and of Introduction: Spinocerebellar ataxias (SCAs), are tri nucleotide measures of REM sleep without atonia repeat length progressive neurodegenerative disorders in which the M. Figorilli 1,R.Ferri2, B. Pereira 3, P. Beudin 4, F. Marrosu 5, cerebellum slowly degenerates, often accompanied by degenera- M. Puliggheddu 5, F. Durif 6, M. Fantini 6 tive changes in the brainstem. Sleep disturbances have been reported 1 Sleep Disorder Center, Department of Public Health & Clinical and in few studies. Molecular Medicine, University of Cagliari, Italy Materials and methods: Objective: To identify and to character- 2 Department of Neurology I.C., Oasi Institute for Research on Mental ize the sleep disturbances in patients with genetically positive Retardation and Brain Aging (IRCCS), Italy spinocerebellar ataxias (SCA 1, 2, 3). Methods: Patients with pro- 3 Biostatistics Unit (DRCI) Clermont-Ferrand, France gressive ataxia were identified and assessed clinically. All the patients 4 Neurology Department, Chu Clermont-Ferrand, France were interviewed with sleep questionnaire. Disease severity was 5 Sleep Disorder Center, Department of Public Health & Clinical and measured with International Ataxia Rating Scale (ICARS) scale. Sleep Molecular Medicine, Italy quality was assessed with Pittsburgh Sleep Quality Index (PSQI), 6 EA 7980, UFR Medicine, University of Clermont, Clermont-Ferrand, Mayo Sleep Questionnaire (MSQ), Epworth Sleepiness Scale (ESS). France Genetically confirmed cases (20 patients) underwent overnight polysomnography (PSG) using 40 channel Galileo Mizar-40 Polysomnography sytem (EB Neuro, Italy). The sleep scoring was Introduction: To assess the sensitivity and specificity of both the carried out according to AASM-2012 using POLYMAN v1.15 (Marco REM sleep behaviour disorder (RBD) single-question screen (RBD1Q) Roessen and Bob Kemp) and sleep variables were analysed across [1] and the RBD-Screening Questionnaire (RBDSQ) [2], as well as sleep cycles using custom scripts written in MATLAB 2012b of measures of REM sleep without atonia (RSWA) assessed with three (Mathworks, USA). different methods, in patients with Parkinson’s disease (PD). = Results: Patients of SCA1, 2, 3 (n = 20; 11 males) were recruited. Materials and methods: Sixty non-demented PD patients (M 37; ± SCA1 = 8; SCA2 = 7; SCA3 = 5; Mean age = 35.49 ± 7.75; Mean mean age: 64 8 years) consecutively evaluated at a movement dis- ICARS = 35.15 ± 18.75; Mean PSQI =3.8 ± 3.6, Mean ESS =2.1 ± 1.7. All order center, filled out both RBD1Q and RBD-SQ, before undergoing patients (8/8) of SCA1 reported no sleep distrubances; 3/7 pa- a full-night video-polysomnographic recording. RSWA was evalu- tients of SCA 2 reported delayed sleep onset; 3/5 patients of SCA3 ated using the Montreal method [3] (% tonic 30-s epochs and % 2-s reported delayed sleep onset and intermittent awakening. And none mini-epochs containing phasic chin EMG activity), the SINBAR [4] of them gave a history suggestive of REM sleep behaviour disor- (% 30-s epochs containing any chin or bilateral Flexor Superficialis der (RBD), rest less leg syndrome (RLS), excessive day time Digitorum (FSD) EMG activity) and the automatic Atonia Index [3]. somnolence (EDS). Polysomnographic analysis showed significant The comparison of these three methods was possible in 32 patients. alteration of sleep architecture predominantly affecting REM sleep Results: RBD was diagnosed in 36 patients following the ICSD-3 ≥ states. Average Sleep Efficiency = 75.6 ± 17.6; N1% = 17.6 ± 12; criteria, including the presence of 27% of 30-s epochs containing N2% = 52 ± 14.6; N3% = 24.5 ± 12.5; REM% = 5.6 ± 6.8. Absent REM any chin or FSD EMG activity. Sensitivity of the RBD-1Q and of the = = sleep states in 70% of SCA2 patients, 60% of SCA3 patients, present RBD-SQ was 55.9% (ROC 0.79) and 52.9% (ROC 0.78), while speci- in all patients in SCA1 but with significant reduction. There is neg- ficity was 90.9% for RBD-1Q and 81.8% for RBDSQ. The simultaneous ative correlation between disease severity (ICARS) and REM use of both questionnaires increases the sensitivity (67.6%, = percentage (p = 0.028). ROC 0.84) without modifying the specificity (76.2%). Taking ICSD-3 Conclusion: In SCAs as the degeneration progresses brain stem RSWA criteria as a reference, the tonic parameters of two visual structures are involved apart from the cerebellum. The more severe methods, namely the Montreal % tonic chin 30-s epochs and the affection of REM sleep States in SCA2 patients and SCA3 supports SINBAR % 30-s epochs containing any chin/FSD activity, showed 100% = early affection of brain stem structures. This needs further explo- sensitivity, 76.9% specificity and ROC 0.93. Atonia Index per- = = ration by neuroimaging and pathology studies. formed slightly lower, with sensitivity 94.7%, specificity 69.2% and ROC = 0.84. The phasic parameters performed significantly worse. Abstracts/Sleep Medicine 16 (2015) S2–S199 S3 The inclusion of FSD does not increase the performance obtained Center for Research Resources and the National Center for Advanc- with the chin alone. ing Translational Sciences, National Institutes of Health, through Conclusion: Screening questionnaires showed good specificity but Grant Number 1 UL1 RR024150-01. low sensitivity; conversely, visual and automatic evaluation of RSWA showed high sensitivity and good specificity for RBD in PD pa- http://dx.doi.org/10.1016/j.sleep.2015.02.005 tients. PD patients might underestimate their RBD during sleep and/ or they might show relatively frequent RSWA without fulfilling the diagnostic criteria for RBD. Motor and non-motor features of Parkinson’s disease in idiopathic REM sleep behaviour disorder References M. Rolinski 1,M.Lawton2,S.Evetts1, F. Baig 1, C. Ruffmann 1, [1] Postuma, et al. Mov Disord 2012. C. Mackay 1, T. Quinnell 3, Z. Zaiwalla 4, Y. Ben-shlomo 2,M.Hu1 [2] Stiasny-Kolster, et al. Mov Disord 2007. 1 University of Oxford, UK [3] Ferri, et al. Sleep Med 2014. 2 University of Bristol, UK [4] Frauscher, et al. Sleep 2012. 3 Papworth Hospital NHS Trust, UK 4 Oxford University Hospitals NHS Trust, UK http://dx.doi.org/10.1016/j.sleep.2015.02.004 Introduction: In some, REM sleep behavior disorder (RBD) is thought to represent the prodromal stage of Parkinson’s disease (PD). Antidepressants increase REM sleep muscle tone in patients with To assess this, we endeavored to elucidate the motor and non- and without REM sleep behavior disorder motor characteristic of RBD, in comparison with healthy controls S. McCarter 1, E. St. Louis 2, D. Sandness 1, K. Arndt 3, M. Erickson 3, and patients with early drug-naïve PD, accounting for potential G. Tabatabai 1,B.Boeve4, M. Silber 4 genetic confounders. 1 Mayo Clinic Center for Sleep Medicine, USA Materials and methods: Patients with idiopathic RBD were re- 2 Department of Neurology and Medicine, Mayo Clinic Center for cruited from the sleep disorders clinic at the John Radcliffe Hospital, Sleep Medicine, USA Oxford and the Papworth Hospital, Cambridge. The diagnosis of RBD 3 Cornell College, USA was made on the basis of polysomnographic evidence according to 4 Department of Neurology, Mayo Clinic Center for Sleep Medicine, standard International Classification of Sleep Disorders-II criteria USA by a consultant specialising in sleep disorders.
Load more

Recommended publications
  • The Neuropsychological Functioning of Men Residing in a Homeless Shelter
    Marquette University e-Publications@Marquette Dissertations, Theses, and Professional Dissertations (1934 -) Projects The Neuropsychological Functioning of Men Residing in a Homeless Shelter Sara Murray Hegerty Marquette University Follow this and additional works at: https://epublications.marquette.edu/dissertations_mu Part of the Psychiatry and Psychology Commons Recommended Citation Hegerty, Sara Murray, "The Neuropsychological Functioning of Men Residing in a Homeless Shelter" (2009). Dissertations (1934 -). 3. https://epublications.marquette.edu/dissertations_mu/3 THE NEUROPSYCHOLOGICAL FUNCTIONING OF MEN RESIDING IN A HOMELESS SHELTER by Sara Murray Hegerty, M.A. A Dissertation submitted to the Faculty of the Graduate School, Marquette University, in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Milwaukee, Wisconsin August 2010 ABSTRACT THE NEUROPSYCHOLOGICAL FUNCTIONING OF MEN RESIDING IN A HOMELESS SHELTER Sara Murray Hegerty, M.A. Marquette University, 2010 The number of homeless individuals in the U.S. has continued to increase, with men comprising the majority of this population. These men are at substantial risk for neuropsychological impairment due to several factors, such as substance misuse, severe mental illness, untreated medical conditions (e.g., diabetes, liver disease, HIV/AIDS), poor nutrition, and the increased likelihood of suffering a traumatic brain injury. Impairments in attention, memory, executive functioning, and other neuropsychological domains can result in poor daily functioning and difficulty engaging in psychological, medical, or educational services. Thus, knowledge of the neuropsychological functioning of homeless men is critical for those who work with this population. Yet data in this area are limited. This study aimed to describe the functioning of men residing in an urban homeless shelter across the domains of attention/concentration, memory, executive functions, language, sensory-motor abilities, general intelligence, and reading ability.
    [Show full text]
  • Staying on Schedule: How to Take Each HIV Medicine
    11 1 11 12 1 11 1 11 12 1 10 2 10 2 10 2 10 2 9 33 9 33 9 33 9 33 8 4 8 4 8 4 8 4 7 6 5 7 6 5 7 6 5 7 6 5 Staying on Schedule How to take each HIV medicine HIV medicines are a key part of your HIV treatment. They can reduce the amount of HIV in your blood to very low levels and help restore your immune system health and your overall health. When you start taking HIV medicines, it is a big commitment. You have to take HIV medicines on time, exactly as they are prescribed, for them to work properly. What this booklet does: • Shows a picture of each HIV medicine. • Lists the amount of the drug in each dose (the amount you take may vary). • Tells you when to take the medicine and whether or not to eat food with it. • Gives general tips for taking each HIV medicine. An HIV medicine schedule is different for everyone. Your doctor or health care provider will work closely with you to decide which medicines to take and how much to1 take. Ask questions before you start taking a medicine When you pick up a new prescription or a refill of an HIV medicine at the drugstore, read the directions carefully. If you don’t understand anything about taking the medicine, ask the pharmacist to explain. Make sure the medicines look the same as the ones you are taking. Check to see if the instructions for taking them are the same instructions given by your doctor or health care provider.
    [Show full text]
  • Preferred Drug List
    Comprehensive PREFERRED DRUG LIST MHS Indiana Effective 04/01/2017 PAGE 1 LAST UPDATED 04/2017 Pharmacy Program MHS Health Plan (MHS) is committed to providing appropriate, high-quality, and cost- effective drug therapy to all MHS members. MHS works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. MHS covers prescription medications and certain over-the-counter (OTC) medications when ordered by an Indiana Medicaid enrolled MHS practitioner. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. For the most current information about the MHS Pharmacy Program you may call Member Services at (877) 647-4848 (TTY/TTD (800) 743-3333) or visit the MHS website www.mhsindiana.com. Preferred Drug List The MHS Preferred Drug List (PDL) is the list of covered drugs. The PDL applies to drugs that members can receive at retail pharmacies. The MHS PDL is continually evaluated by the MHS Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost-effective use of medications. The Committee is composed of the MHS Medical Director, MHS Pharmacy Director, and several Indiana physicians, pharmacists, and specialists. Pharmacy Benefit Manager Envolve Pharmacy Solutions (EPS) is our Pharmacy Benefit Manager. MHS works with EPS to process all pharmacy claims for prescribed drugs. Some drugs on the MHS PDL require PA, and EPS is responsible for administering this process. Specialty Drugs Certain medications are only covered when supplied by MHS’ specialty pharmacy provider. AcariaHealth is our specialty pharmacy provider.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • 7Th World Congress on ADHD: from Child to Adult Disorder
    ADHD Atten Def Hyp Disord (2019) 11(Suppl 1):S1–S89 https://doi.org/10.1007/s12402-019-00295-7 ABSTRACTS Ó Springer-Verlag GmbH Austria, part of Springer Nature 2019 7th World Congress on ADHD: From Child to Adult Disorder 25th–28th April, Lisbon Portugal Editors: Manfred Gerlach, Wu¨rzburg Peter Riederer, Wu¨rzburg Andreas Warnke, Wu¨rzburg Luis Rohde, Porto Alegre 123 S2 ABSTRACTS Introduction Dear Colleagues and Friends, We are pleased to have received more than 180 poster abstracts as well as more than 100 poster abstracts from young scientists and clinicians (\ 35 years) who applied for our Young Scientists’ Award. Of all abstracts submitted by our young colleagues, the Scientific Programme Committee has selected the best eight. The authors have been invited to give a presentation as part of our two Young Scientist Award Sessions and to receive a prize money in the amount of 500 Euros. With this approach, we intend to highlight the importance of original scientific contributions, especially from our young colleagues. In this volume, the abstracts of our two Young Scientist Award Sessions come first, followed by regular poster abstracts. These have been organized by topics: Aetiology, Autism Spectrum Disorders, Co-morbidity, Diagnosis, Electrophysiology, Epidemiology, Experimental Models, Genetics, Neuroimaging, Non-pharmacological Treatment, Pathophysiology, Pharmacological Treatment, Quality of Life/Caregiver Burden, Substance Use Disorders and Miscellaneous. Submitted abstracts have not been modified in any way. Please, do not just read the selected poster abstracts, we also encourage you to actively discuss and share your ideas with our young colleagues. Finally, we would like thank all our speakers, contributors and sponsors of our 7th World Congress on ADHD: from Childhood to Adult Disease, and welcome you to join—what we are sure will be—a very enjoyable and highly informative event.
    [Show full text]
  • Preferred Drug List (PDL)
    Preferred Drug List (PDL) New Jersey – MLTSS Effective Date: 7/15/2021 © 2021 United HealthCare Services, Inc. All Rights Reserved. UnitedHealthcare Community Plan does not treat members differently because of sex, age, race, color, disability or national origin. If you think you were treated unfairly because of your sex, age, race, color, disability or national origin, you can send a complaint to: Civil Rights Coordinator UnitedHealthcare Civil Rights Grievance P.O. Box 30608 Salt Lake City, UTAH 84130 [email protected] You must send the complaint within 60 days of when you found out about it. A decision will be sent to you within 30 days. If you disagree with the decision, you have 15 days to ask us to look at it again. If you need help with your complaint, please call the toll-free member phone number listed on your health plan member ID card, TTY 711, 24 hours a day, 7 days a week. You can also file a complaint with the U.S. Dept. of Health and Human Services. Online: https://ocrportal.hhs.gov/ocr/portal/lobby.jsf Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Phone: Toll-free 1-800-368-1019, 1-800-537-7697 (TDD) Mail: U.S. Dept. of Health and Human Services 200 Independence Avenue SW Room 509F, HHH Building Washington, D.C. 20201 If you need help with your complaint, please call the toll-free member phone number listed on your member ID card. We provide free services to help you communicate with us, such as letters in other languages or large print.
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]
  • An Analysis of the Auditory-Verbal and Visual-Figural Learning and Memory Patterns of College Students with Learning Disabilities
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-1996 An Analysis of the Auditory-Verbal and Visual-Figural Learning and Memory Patterns of College Students with Learning Disabilities Robert K. Eckert Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Psychology Commons Recommended Citation Eckert, Robert K., "An Analysis of the Auditory-Verbal and Visual-Figural Learning and Memory Patterns of College Students with Learning Disabilities" (1996). Dissertations. 1688. https://scholarworks.wmich.edu/dissertations/1688 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. AN ANALYSIS OF THE AUDITORY-VERBAL AND VISUAL-FIGURAL LEARNING AND MEMORY PATTERNS OF COLLEGE STUDENTS WITH LEARNING DISABILITIES by Robert K. Eckert A Dissertation Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Psychology Western Michigan University Kalamazoo, Michigan June 1996 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. AN ANALYSIS OF THE AUDITORY-VERBAL AND VISUAL-FIGURAL LEARNING AND MEMORY PATTERNS OF COLLEGE STUDENTS WITH LEARNING DISABILITIES Robert K. Eckert, Ph.D. Western Michigan University, 1996 The validity of the California Verbal Learning Test (CVLT) has been established with most clinical neuropsychological populations; however, no published work in the area of CVLT performance in adults with learning disabilities (LD) exists, despite the authors' assertion that the test is a useful psychometric measure for this population (Delis, Kramer, Kaplan, & Ober, 1987).
    [Show full text]
  • Bk Sans 005737.Pdf
    TABLE OF CONTENTS Procter & Gamble’s Earnings Per Share .3 Coca-Cola’s Earnings Per Share .3 Johnson & Johnson’s Earnings Per Share .4 United Continental’s Earnings Per Share .4 Ford Motor Company’s Earnings Per Share .5 Advance Micro Devices, Inc.’s Earnings Per Share .5 Compare Coca-Cola to Ford Motor Company .6 American Express Company .7 American Express Company Per Share Earnings History .8 The Bank of New York Mellon (BNY Mellon) .9 BNY Mellon EPS History / BNY Mellon BVPS History .10 Coca-Cola Company .11 ConocoPhillips .12 ConocoPhillips EPS History / ConocoPhillips BVPS History .13 Costco Wholesale Corporation .14 Costco EPS History / Costco BVPS History .15 GlaxoSmithKline .16 GSK’s brand-name products .17 GlaxoSmithKline’ Profile / GlaxoSmithKline’ History .18 Johnson & Johnson .19 Johnson & Johnson Per Share Book Value History .20 Kraft Foods, Inc .21 Kraft Foods EPS History / Kraft Foods BVPS History .22 Moody’s Corporation .23 Moody’s Corporation EPS History .24 Procter & Gamble Company .25 Procter & Gamble BVPS History .26 Sanofi S. A. .27 Sanofi A.S EPS ADR History / Sanofi A.S BVPS History .28 Torchmark Corporatio .29 Torchmark Corporation EPS History / Torchmark Corporation BVPS History .30 Union Pacific Corporation .31 Union Pacific Corporation NPM (Net Profit Margin) History .32 Union Pacific Corporation BVPS History / Union Pacific Corporation EPS History .32 U.S. Bancorp .33 U.S. Bankcorp EPS History / U.S. Bankcorp BVPS History .34 Wal-Mart Stores, Inc. .35 Walmart EPS History / Walmart BVPS History .36 Washington
    [Show full text]
  • View Annual Report
    Connecting... Annual Report 2001 Mission Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer. Our Spirit We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Strategic Intent We want to become the indisputable leader in our industry. GlaxoSmithKline plc is an English public limited company. Its shares are listed on the London Stock Exchange and the New York Stock Exchange. GlaxoSmithKline plc acquired Glaxo Wellcome plc and SmithKline Beecham plc on 27th December 2000 by way of a scheme of arrangement for the merger of the two companies which became effective on 27th December 2000. This report is the Annual Report of GlaxoSmithKline plc for the year ended 31st December 2001. It comprises in a single document the Annual Report of the company in accordance with United Kingdom requirements and the Annual Report on Form 20-F to the Securities and Exchange Commission in the United States of America. A summary report on the year, the Annual Review 2001, intended for the investor not needing the full detail of the Annual Report, is produced as a separate document. The Annual Review includes the joint statement by the Chairman and Chief Executive Officer, a summary review of operations, summary financial statements and a summary remuneration report. The Annual Review is issued to all shareholders.
    [Show full text]
  • Investor Information 2014
    Investor information reportStrategic In this section Quarterly trend 218 Five year record 222 Product development pipeline 225 Products, competition and intellectual property 229 Risk factors 232 Share capital and share price 242 remuneration & Governance Dividends 244 Tax information for shareholders 244 Annual General Meeting 2015 245 US law and regulation 247 Shareholder services and contacts 249 Glossary of terms and index 251 Financial statementsFinancial Investor information Investor GSK Annual Report 2014 217 Financial record Strategic reportStrategic Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2014. Income statement – total 12 months 2014 Q4 2014 £m CER% £% £m CER% £% Turnover – Pharmaceuticals and Vaccines 18,670 (6) (12) 5,070 (7) (10) – Consumer Healthcare 4,336 (11) (18) 1,116 (7) (10) Total turnover 23,006 (7) (13) 6,186 (7) (10) Cost of sales (7,323) (11) (15) (2,029) (18) (20) Selling, general and administration (8,246) 4 (3) (2,207) 4 – Research and development (3,450) (8) (12) (979) (7) (9) Royalty income 310 (18) (20) 67 (31) (32) Other operating income (700) (347) Operating profit 3,597 (40) (49) 691 (69) (72) Governance & remuneration & Governance Net finance costs (659) (171) Profit on disposal of interest in associates and joint ventures – – Share of after tax profits of associates and joint ventures 30 11 Profit before taxation 2,968 (46) (55) 531 (77) (79) Taxation (137) 494 Tax rate % 4.6% (93.0)% Profit after taxation for the period 2,831 (41) (50)
    [Show full text]
  • Included See Page 24 for More Information
    16204 N. Florida Ave. • Lutz, FL 33549 PRSRT STD U.S. POSTAGE PAID Professional Assessment Products Bolingbrook IL Permit # 422 July 2018 Leaving talent assessment Are there more than 10 assessment professionals on your team? to chance? Contact our Sales and National Accounts team for additional benets. See page 22. Identify talent Life is better when Develop employees Grow your business everyone’s included See page 24 for more information. A test that removes barriers is inherently a more In addition, items that show differential item inclusive measure. functioning associated with gender or ethnicity The RIAS-2 affords cultural sensitivity by have been eliminated. eliminating the need to read items in English. Bottom line: The RIAS-2 is culturally sensitive. RIAS-2 For more information, see page 150 Reynolds Intellectual Assessment Scales™, Second Edition or visit parinc.com/RIAS2. July 2018 Looking for something a little more scientic? Add technology and objectivity to the hiring equation. Recruiting is too important to leave to chance. Hiring the wrong person lowers performance and destroys organizational morale. The costs in turnover alone are incredible. Go beyond gut instincts. Let InVista’s talent assessment expertise fortify your company’s recruitment process with science and technology. We make it easy to make the best talent decisions. To learn more, see page 24 or visit invistatalent.com. a division of From the CEO Check out Dear Valued Customers, this catalog’s In our April catalog, we looked back in recognition of PAR’s 40th featured items anniversary. Once again, this is a milestone that we owe to you, our Customers, and we thank you for your unwavering support over the past 40 years.
    [Show full text]